SCHEMBL1663733

SCHEMBL1663733

CC(=O)c1c(O)ccc2c(=O)n(-c3ccc(Cl)cc3)c(C(C)C)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 1/20 0.39
PDE10A Q9Y233 2/20 0.38
GRM1 Q13255 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR6 P50406 1/20 0.35
HPD P32754 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAT2A P31153 1/20 0.35
ALDH1A1 P00352 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3R2 O00459 1/20 0.34
PIK3CG P48736 1/20 0.34
GRM5 P41594 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10446286 0.86 ESR1 (0.44) ESR1ESR2TRPV1KDM4EPDE10A
SCHEMBL10446162 0.85 ESR1 (0.45) ESR1ESR2TRPV1KDM4EKMT2A
SCHEMBL1663064 0.85 TRPV1 (0.60) ESR1ESR2TRPV1KDM4EPDE10A
SCHEMBL14396195 0.84 ESR1 (0.44) ESR1ESR2TRPV1KDM4EGRM1
SCHEMBL1663871 0.83 ESR1 (0.44) ESR1ESR2TRPV1KDM4EGRM1
SCHEMBL10446404 0.82 ESR1 (0.43) ESR1ESR2TRPV1KDM4EKMT2A
SCHEMBL1663998 0.81 ESR1 (0.42) ESR1ESR2TRPV1KDM4EPDE10A
SCHEMBL12605322 0.81 SMN1; SMN2 (0.44) ESR1ESR2TRPV1KDM4EPDE10A
SCHEMBL1664062 0.81 ESR1 (0.42) ESR1ESR2TRPV1KDM4EKMT2A
SCHEMBL10446287 0.81 ESR1 (0.42) ESR1ESR2TRPV1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 ESR1 1321/4885ESR2 2159/4885TRPV1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.